KR20160127126A - 우울증 및 주요 우울증을 치료하기 위한 방법 - Google Patents

우울증 및 주요 우울증을 치료하기 위한 방법 Download PDF

Info

Publication number
KR20160127126A
KR20160127126A KR1020167027125A KR20167027125A KR20160127126A KR 20160127126 A KR20160127126 A KR 20160127126A KR 1020167027125 A KR1020167027125 A KR 1020167027125A KR 20167027125 A KR20167027125 A KR 20167027125A KR 20160127126 A KR20160127126 A KR 20160127126A
Authority
KR
South Korea
Prior art keywords
variant
cacna1c
zscan4
primers
pair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167027125A
Other languages
English (en)
Korean (ko)
Inventor
에릭 레이
자레스 프렌치-멀린
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20160127126A publication Critical patent/KR20160127126A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167027125A 2014-03-05 2015-03-04 우울증 및 주요 우울증을 치료하기 위한 방법 Withdrawn KR20160127126A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461948529P 2014-03-05 2014-03-05
US61/948,529 2014-03-05
US201462061417P 2014-10-08 2014-10-08
US62/061,417 2014-10-08
PCT/US2015/018701 WO2015134585A1 (en) 2014-03-05 2015-03-04 Method for treating depression and major depressive disorder

Publications (1)

Publication Number Publication Date
KR20160127126A true KR20160127126A (ko) 2016-11-02

Family

ID=54055831

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027125A Withdrawn KR20160127126A (ko) 2014-03-05 2015-03-04 우울증 및 주요 우울증을 치료하기 위한 방법

Country Status (12)

Country Link
US (1) US20170137880A1 (enExample)
EP (1) EP3114239A4 (enExample)
JP (1) JP2017512204A (enExample)
KR (1) KR20160127126A (enExample)
CN (1) CN106536751A (enExample)
AU (1) AU2015227296A1 (enExample)
CA (1) CA2940683A1 (enExample)
IL (1) IL247379A0 (enExample)
MA (1) MA39485A (enExample)
MX (1) MX2016011384A (enExample)
RU (1) RU2016138574A (enExample)
WO (1) WO2015134585A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
PL3528811T3 (pl) * 2017-03-30 2022-01-10 Rundle Research, LLC Wortioksetyna i inhibitory mao do leczenia depresji
EP3909600A1 (en) * 2020-05-12 2021-11-17 International Centre For Genetic Engineering And Biotechnology - ICGEB Emid2 protein as anti-cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
EP2581454B1 (en) * 2008-01-17 2015-09-16 Suregene LLC Genetic markers of mental illness
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2622101A4 (en) * 2010-10-01 2014-04-02 Rigshospitalet Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors
US9243464B2 (en) * 2011-02-10 2016-01-26 Baker Hughes Incorporated Flow control device and methods for using same
WO2012109565A1 (en) * 2011-02-10 2012-08-16 Neurotherics, Llc Genetic identification of response to antidepressant medications
AU2012340015B2 (en) * 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment

Also Published As

Publication number Publication date
EP3114239A1 (en) 2017-01-11
RU2016138574A (ru) 2018-04-06
CN106536751A (zh) 2017-03-22
WO2015134585A1 (en) 2015-09-11
MX2016011384A (es) 2017-05-01
JP2017512204A (ja) 2017-05-18
CA2940683A1 (en) 2015-09-11
US20170137880A1 (en) 2017-05-18
RU2016138574A3 (enExample) 2018-10-12
IL247379A0 (en) 2016-11-30
AU2015227296A1 (en) 2016-09-08
MA39485A (fr) 2015-09-11
EP3114239A4 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
US20090191568A1 (en) Methods and compositions for predicting compliance with an antidepressant treatment regimen
US20210222245A1 (en) Autism associated genetic markers
US12065702B2 (en) Mitochondrial markers of neurodegenerative diseases
US10072289B2 (en) Genetic addiction risk analysis for RDS severity index
Lin et al. Gene–gene interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine kinase receptor 2 genes in geriatric depression
Blaveri et al. Expression profiling of a genetic animal model of depression reveals novel molecular pathways underlying depressive-like behaviours
US10954563B2 (en) Method for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment
KR20160127126A (ko) 우울증 및 주요 우울증을 치료하기 위한 방법
JP2007526764A (ja) アルツハイマー病の発症年齢に関連するａｐｏｅ遺伝子マーカー
CN115515680A (zh) 用于评估神经递质转运蛋白抑制剂的功效的组合物和方法
US20050255498A1 (en) APOC1 genetic markers associated with age of onset of Alzheimer's Disease
US20190078161A1 (en) Method for identifying clinical trial responders from a placebo group in major depression
JP2007510404A (ja) アルツハイマー病の発症年齢に関連するｎｔｒｋ１遺伝子マーカー
JP2014518071A (ja) カロリー制限およびカロリー制限模倣物の同定用マーカー
KR102883401B1 (ko) 우울증 진단용 단일염기다형성 및 이의 용도
TW201625799A (zh) 治療憂鬱症和重度憂鬱症之方法
WO2016123543A1 (en) Method for treating schizophrenia comprising administering lurasidone
HK40083504A (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000